Patent ID: 11952365
Assignee: ALIGOS THERAPEUTICS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 5:
6. The compound of claim 1, wherein Ring A1 is an unsubstituted or a substituted azetidine, wherein the azetidine is connected to a cyclic moiety selected from the group consisting of a monocyclic C3-7 cycloalkyl, a bicyclic C5-9 cycloalkyl, a monocyclic C3-7 cycloalkenyl, a bicyclic C5-9 cycloalkenyl and phenyl, wherein the cyclic moiety is connected to the azetidine in a fused-fashion or a spiro-fashion that can be optionally substituted with one or more moieties independently selected from the group consisting of halogen, an unsubstituted C1-4 alkyl and an unsubstituted C2-4 alkenyl, or an unsubstituted or a substituted pyrrolidine, wherein the pyrrolidine is connected to a cyclic moiety selected from the group consisting of a monocyclic C3-7 cycloalkyl, a bicyclic C5-9 cycloalkyl, a monocyclic C3-7 cycloalkenyl, a bicyclic C5-9 cycloalkenyl and phenyl, wherein the cyclic moiety is connected to the pyrrolidine in a fused-fashion or a spiro-fashion that can be optionally substituted with one or more moieties independently selected from the group consisting of halogen, an unsubstituted C1-4 alkyl and an unsubstituted C2-4 alkenyl, or an unsubstituted or a substituted piperidine, wherein the piperidine is connected to a cyclic moiety selected from the group consisting of a monocyclic C3-7 cycloalkyl, a bicyclic C5-9 cycloalkyl, a monocyclic C3-7 cycloalkenyl, a bicyclic C5-9 cycloalkenyl and phenyl, wherein the cyclic moiety is connected to the piperidine in a fused-fashion or a spiro-fashion that can be optionally substituted with one or more moieties independently selected from the group consisting of halogen, an unsubstituted C1-4 alkyl and an unsubstituted C2-4 alkenyl.